On Friday, Expeditors International of Washington (NASDAQ:EXPD)’s shares declined -0.78% to $48.04.
Expeditors International of Washington (EXPD) declared the appointment of Daniel R. Wall to the position of President, Global Products. Mr. Wall will assume the Company’s product leadership role presently held by R. Jordan Gates. On April 1, 2015 the Company declared Mr. Gates’ intention to retire in 2015. His retirement will become effective on July 31, 2015.
Mr. Wall started his 28-year career at Expeditors as a messenger responsible for clients’ Customs documents in the Seattle branch office in 1987. During the course of his career, he has held many positions counting the District Manager of the Company’s Denver and Seattle offices, Global Director of Account Administration, and the position he presently holds as the Company’s Senior Vice President responsible for Ocean Services and Order Administration.
Expeditors International of Washington, Inc. provides logistics services. The company’s services comprise air and ocean freight consolidation and forwarding, customs clearance, warehousing and distribution, purchase order administration, vendor consolidation, time-definite transportation services, cargo insurance, and other logistics solutions. It acts as a freight consolidator or as an agent for the airline, which carries the shipment.
Sequenom, Inc. (NASDAQ:SQNM)’s shares gained 0.62% to $3.24.
Sequenom, Inc. (SQNM) a life sciences company committed to enabling healthier lives through the development of innovative products and services, recently declared that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been designated to the Audit and Nominating and Corporate Governance committees of the Company’s Board of Directors.
Dr. Mackey is presently the Chief Executive Officer of CYPrus Therapeutics, Inc., a privately-held small molecule pharmaceutical development company. She is a Special Advisor to Fortis Advisors LLC, and serves on the Scientific Advisory Boards of FHOOSH, Inc. and Cypher Genomics. In addition, Dr. Mackey is a director and a member of the Finance and Audit & Compliance Committees of Rady Children’s Hospital and is past-chair of CONNECT. Dr. Mackey presently serves on the boards of privately-held companies Cour Pharmaceutical Development Company (Chair), Evolve Biosystems, Inc. and Viventia Bio, Inc.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
At the end of Friday’s trade, Kansas City Southern (NYSE:KSU)‘s shares dipped -0.96% to $95.22.
Kansas City Southern (KSU) has declared that its U.S. partner, The Kansas City Southern Railway Company (KCSR), has reached a contract with Sasol Chemicals (USA) LLC (Sasol) for the construction and long-term lease of a storage-in-transit (SIT) rail yard to support Sasol’s new ethane cracker and derivatives project in Lake Charles, La. In addition to building the SIT yard for lease to Sasol, KCSR will replace and expand its existing rail car classification yard in Mossville, La.
In October 2014, Sasol declared a final investment decision on an $8.1 billion ethane cracker and derivatives complex in Louisiana. At the heart of the project is an ethane cracker that will produce 1.5 million tons of ethylene annually, benefitting from noteworthyeconomies of scale. The complex also comprises six chemical manufacturing plants. An additional $800 million will be invested in infrastructure and utility improvements, in addition to land acquisition, to establish the Lakes Charles location as an integrated, multi-asset site that will enable growth for decades to come. Construction is underway, and the company anticipates that the facility will achieve beneficial operation in 2018.
Kansas City Southern, through its auxiliaries, engages in the freight rail transportation business. It operates north/south rail route between Kansas City, Missouri, and various ports along the Gulf of Mexico in Alabama, Louisiana, Mississippi, and Texas in the midwest and southeast regions of the United States.
DS Healthcare Group Inc (NASDAQ:DSKX), ended its Friday’s trading session with 4.95% gain, and closed at $4.66.
DS Healthcare Group Inc (DSKX) DS Healthcare Group is searching for a Chief Marketing Officer, to bolster sales of its consumer products business.
The company has not had any marketing activities to date and its entire revenue stream comes from organic sales through its distribution network. Focusing on its core competencies of developing personal care products and new drug therapies in previous times, the company will now support its retail distribution with a robust marketing plan.
The ideal candidate is an practiced executive who can link company efforts and use of resources to specific growth and performance objectives. The Chief Marketing Officer must execute marketing strategies that are central to DS Healthcare’s corporate DNA of disruptive product innovation and act as the voice of customers internally.
DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally. Its hair care products comprise Revita and Revita LT shampoos, and Revita.Cor conditioner for hair growth stimulation; Dandrene, an antifungal shampoo to treat itchy scalp and dandruff; and Spectral line of products comprising Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair through various pathways, in addition to Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
